Terms: = Liver cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Prognosis
134 results:
1. Identification of ASF1A and HJURP by global H3-H4 histone chaperone analysis as a prognostic two-gene model in hepatocellular carcinoma.
Liu Y; Liu S; Jing R; Li C; Guo Y; Cai Z; Xi P; Dai P; Jia L; Zhu H; Zhang X
Sci Rep; 2024 Apr; 14(1):7666. PubMed ID: 38561384
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNA circTATDN3 promotes the Warburg effect and proliferation in colorectal cancer.
Lin J; Zhong W; Lyu Z; Peng J; Rong Y; Zeng K; Lai J; Wu D; Wang J; Li Y; Zheng J; Zhang J; Pan Z
Cancer Lett; 2024 May; 589():216825. PubMed ID: 38548218
[TBL] [Abstract] [Full Text] [Related]
3. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity-induced NGF-NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti-tumor immunotherapy with PD-1 mAb in hepatocellular carcinoma.
Wang X; Yang T; Shi S; Xu C; Wang F; Dai D; Guan G; Zhang Y; Wang S; Wang J; Zhang B; Liu P; Bai X; Jin Y; Li X; Zhu C; Chen D; Xu Q; Guo Y
Cancer Med; 2024 Feb; 13(3):e6736. PubMed ID: 38204220
[TBL] [Abstract] [Full Text] [Related]
5. Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma.
Kato H; Hayami S; Ueno M; Suzaki N; Nakamura M; Yoshimura T; Miyamoto A; Shigekawa Y; Okada KI; Miyazawa M; Kitahata Y; Ehata S; Hamamoto R; Yamaue H; Kawai M
Cancer Sci; 2024 Feb; 115(2):385-400. PubMed ID: 38082550
[TBL] [Abstract] [Full Text] [Related]
6. BAP18 acting as a novel peroxisome proliferator-activated receptor α co-regulator contributes to hepatocellular carcinoma progression.
Liu W; Wang S; Lin L; Zou R; Sun H; Zeng K; Wu Y; Li Y; Shigeaki K; Wang X; Wang C; Zhao Y
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166974. PubMed ID: 38042310
[TBL] [Abstract] [Full Text] [Related]
7. Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review.
Zhang S; Liao Z; Li S; Luo Y
Medicine (Baltimore); 2023 Oct; 102(42):e35571. PubMed ID: 37861491
[TBL] [Abstract] [Full Text] [Related]
8. Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Li JY; Tian T; Han B; Yang T; Guo YX; Wu JY; Chen YS; Yang Q; Xie RJ
World J Gastroenterol; 2023 Sep; 29(34):5038-5053. PubMed ID: 37753370
[TBL] [Abstract] [Full Text] [Related]
9. The ALKBH5/SOX4 axis promotes liver cancer stem cell properties via activating the SHH signaling pathway.
Yang Q; Liang Y; Shi Y; Shang J; Huang X
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15499-15510. PubMed ID: 37646828
[TBL] [Abstract] [Full Text] [Related]
10. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract] [Full Text] [Related]
12. Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway.
Miao H; Geng Y; Li Y; Tang S; Feng F; Li W; Li Y; Liu L; Zhang R; Qiu S; Wu Y; Wang Z; Wang Z; Shao Z; Liu K; Zou L; Yang M; Zhao Y; Chen C; Li Z; Zhang D; Peng P; Qiang X; Wu F; He Y; Chen L; Xiang D; Jiang X; Li M; Liu Y; Liu Y
Cell Oncol (Dordr); 2022 Aug; 45(4):689-708. PubMed ID: 35870050
[TBL] [Abstract] [Full Text] [Related]
13. Identification of CFHR4 as a Potential prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.
Yu H; Wang C; Ke S; Bai M; Xu Y; Lu S; Feng Z; Qian B; Xu Y; Zhou M; Li Z; Yin B; Li X; Hua Y; Zhou Y; Pan S; Fu Y; Ma Y
Front Immunol; 2022; 13():892750. PubMed ID: 35812416
[TBL] [Abstract] [Full Text] [Related]
14. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.
Zhang Z; Xia F; Xu Z; Peng J; Kang F; Li J; Zhang W; Hong Q
Sci Rep; 2022 May; 12(1):8886. PubMed ID: 35614201
[TBL] [Abstract] [Full Text] [Related]
15. Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci.
Ying Y; Wang M; Chen Y; Li M; Ma C; Zhang J; Huang X; Jia M; Zeng J; Wang Y; Li L; Wang X; Tao Q; Shu XS
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2120633119. PubMed ID: 35605119
[TBL] [Abstract] [Full Text] [Related]
16. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract] [Full Text] [Related]
17. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Salani F; Latarani M; Casadei-Gardini A; Gangadharannambiar P; Fornaro L; Vivaldi C; Pecora I; Massa V; Marisi G; Canale M; Ulivi P; Scartozzi M; Eccleston M; Masi G; Crea F
Epigenomics; 2022 May; 14(9):507-517. PubMed ID: 35473355
[TBL] [Abstract] [Full Text] [Related]
18. A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma.
Shi Q; Liu Y; Lu M; Lei QY; Chen Z; Wang L; He X
Comput Biol Med; 2022 May; 144():105376. PubMed ID: 35286894
[TBL] [Abstract] [Full Text] [Related]
19. 3-Mercaptopyruvate sulfurtransferase represses tumour progression and predicts prognosis in hepatocellular carcinoma.
Li M; Song X; Jin Q; Chen Y; Zhang J; Gao J; Cen L; Lin Y; Xu C; He X; Li Y; Yu C
Liver Int; 2022 May; 42(5):1173-1184. PubMed ID: 35243746
[TBL] [Abstract] [Full Text] [Related]
20. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract] [Full Text] [Related]
[Next]
